Comparative Pharmacology
Head-to-head clinical analysis: DRALZINE versus RAUWOLFIA SERPENTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRALZINE versus RAUWOLFIA SERPENTINA.
DRALZINE vs RAUWOLFIA SERPENTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.
Rauwolfia serpentina alkaloids (e.g., reserpine) deplete catecholamines and serotonin from central and peripheral neurons by binding irreversibly to vesicular monoamine transporters (VMAT), leading to reduced sympathetic outflow and decreased blood pressure.
Oral: 50-100 mg twice daily; maximum 200 mg/day.
Oral: 50–100 mg twice daily for 2 weeks, then maintenance of 50–100 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 2-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment.
Terminal elimination half-life: 40-100 hours (mean ~70 h). Accumulation occurs with chronic dosing; steady-state reached in ~2-3 weeks.
Primarily renal (70-90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <10%.
Renal (urinary) elimination of unchanged drug and metabolites: approximately 60-70% as metabolites, <1% unchanged. Fecal excretion: 30-40% via bile.
Category C
Category C
Antihypertensive
Antihypertensive